Caprock Group LLC Purchases Shares of 20,000 Accuray Incorporated (NASDAQ:ARAY)

Caprock Group LLC acquired a new position in shares of Accuray Incorporated (NASDAQ:ARAY) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 20,000 shares of the medical equipment provider’s stock, valued at approximately $36,000.

Other hedge funds also recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its holdings in Accuray by 13.3% in the second quarter. The Manufacturers Life Insurance Company now owns 44,936 shares of the medical equipment provider’s stock worth $82,000 after purchasing an additional 5,273 shares during the period. Price T Rowe Associates Inc. MD increased its position in Accuray by 9.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider’s stock valued at $181,000 after buying an additional 6,583 shares in the last quarter. Renaissance Technologies LLC raised its stake in Accuray by 0.3% during the 2nd quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock worth $5,118,000 after buying an additional 7,500 shares during the period. Bank of New York Mellon Corp boosted its holdings in Accuray by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 279,426 shares of the medical equipment provider’s stock worth $509,000 after acquiring an additional 8,864 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its holdings in Accuray by 253,483.3% in the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 15,209 shares in the last quarter. Institutional investors own 64.08% of the company’s stock.

Accuray Trading Up 5.2 %

NASDAQ:ARAY opened at $2.03 on Tuesday. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. Accuray Incorporated has a one year low of $1.40 and a one year high of $3.05. The company has a market cap of $204.15 million, a PE ratio of -11.76 and a beta of 1.40. The firm has a 50-day moving average of $1.84 and a 200-day moving average of $1.83.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to analyst estimates of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same period in the previous year, the company posted ($0.03) EPS. As a group, equities research analysts expect that Accuray Incorporated will post 0.01 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.